Statin treatment is associated with reduction in serum levels of receptor activator of NF- B ligand and neutrophil activation in patients with severe carotid stenosis

Mediators of Inflammation

Volumn 2014, Issue , 2014, Pages

  Lenglet, Sébastien ^a   Quercioli, Alessandra ^a   Fabre, Mathias ^a   Galan, Katia ^a   Pelli, Graziano ^a   Nencioni, Alessio ^b   Bauer, Inga ^b   Pende, Aldo ^b   Python, Magaly ^a   Bertolotto, Maria ^b   Spinella, Giovanni ^c   Pane, Bianca ^c   Palombo, Domenico ^c   Dallegri, Franco ^b   Mach, François ^a   Vuilleumier, Nicolas ^d   Montecucco, Fabrizio ^a,b,d  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; GELATINASE B; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEUKOCYTE ELASTASE; LIPID; MYELOPEROXIDASE; NEUTROPHIL COLLAGENASE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPONTIN; OSTEOPROTEGERIN; ROSUVASTATIN; SIMVASTATIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TISSUE INHIBITOR OF METALLOPROTEINASE 4; FLUOROBENZENE; HEPTANOIC ACID DERIVATIVE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; MMP9 PROTEIN, HUMAN; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; SPP1 PROTEIN, HUMAN; SULFONAMIDE; TNFRSF11B PROTEIN, HUMAN; TNFSF11 PROTEIN, HUMAN;

AGED; ARTICLE; ASYMPTOMATIC DISEASE; ATHEROSCLEROTIC PLAQUE; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CAROTID ARTERY OBSTRUCTION; CAROTID ENDARTERECTOMY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LEUKOCYTE ACTIVATION; LIMIT OF DETECTION; MACROPHAGE; MALE; NEUTROPHIL CHEMOTAXIS; PILOT STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REAL TIME POLYMERASE CHAIN REACTION; SMOOTH MUSCLE FIBER; ATHEROSCLEROSIS; BLOOD; COHORT ANALYSIS; CYTOLOGY; DRUG EFFECT; METABOLISM; MIDDLE AGED; NEUTROPHIL; PATHOLOGY; RISK FACTOR;

AGED; ATHEROSCLEROSIS; CAROTID STENOSIS; COHORT STUDIES; FEMALE; FLUOROBENZENES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NEUTROPHIL ACTIVATION; NEUTROPHILS; NF-KAPPA B; OSTEOPONTIN; OSTEOPROTEGERIN; PYRIMIDINES; PYRROLES; RANK LIGAND; RISK FACTORS; RNA, MESSENGER; SIMVASTATIN; SULFONAMIDES;

EID: 84896832281     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2014/720987     Document Type: Article

References (30)

1. Yeboah J., Carr J. J., Terry J. G., Ding J., Zeb I., Liu S., Nasir K., Post W., Blumenthal R. S., Budoff M. J., Computed tomography-derived cardiovascular risk markers, incident cardiovascular events, and all-cause mortality in nondiabetics: the multi-ethnic study of atherosclerosis. European Journal of Preventive Cardiology. In press
2. Hermann D. M., Gronewold J., Lehmann N., Moebus S., Jöckel K.-H., Bauer M., Erbel R., Coronary artery calcification is an independent stroke predictor in the general population. Stroke 2013 44 1008 1013 10.1161/STROKEAHA.111.678078
3. Shaalan W. E., Cheng H., Gewertz B., McKinsey J. F., Schwartz L. B., Katz D., Cao D., Desai T., Glagov S., Bassiouny H. S., Degree of carotid plaque calcification in relation to symptomatic outcome and plaque inflammation. Journal of Vascular Surgery 2004 40 2 262 269 2-s2.0-3442886204 10.1016/j.jvs.2004.04.025
4. Naghavi M., Libby P., Falk E., Casscells S. W., Litovsky S., Rumberger J., Badimon J. J., Stefanadis C., Moreno P., Pasterkamp G., Fayad Z., Stone P. H., Waxman S., Raggi P., Madjid M., Zarrabi A., Burke A., Yuan C., Fitzgerald P. J., Siscovick D. S., De Korte C. L., Aikawa M., Airaksinen K. E. J., Assmann G., Becker C. R., Chesebro J. H., Farb A., Galis Z. S., Jackson C., Jang I.-K., Koenig W., Lodder R. A., March K., Demirovic J., Navab M., Priori S. G., Rekhter M. D., Bahr R., Grundy S. M., Mehran R., Colombo A., Boerwinkle E., Ballantyne C., Insull W. Jr., Schwartz R. S., Vogel R., Serruys P. W., Hansson G. K., Faxon D. P., Kaul S., Drexler H., Greenland P., Muller J. E., Virmani R., Ridker P. M., Zipes D. P., Shah P. K., Willerson J. T., From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part I. Circulation 2003 108 14 1664 1672 2-s2.0-0141885294 10.1161/01.CIR. 0000087480.94275.97 (Pubitemid 37243650)
5. Naghavi M., Libby P., Falk E., Casscells S. W., Litovsky S., Rumberger J., Badimon J. J., Stefanadis C., Moreno P., Pasterkamp G., Fayad Z., Stone P. H., Waxman S., Raggi P., Madjid M., Zarrabi A., Burke A., Yuan C., Fitzgerald P. J., Siscovick D. S., De Korte C. L., Aikawa M., Airaksinen K. E. J., Assmann G., Becker C. R., Chesebro J. H., Farb A., Galis Z. S., Jackson C., Jang I.-K., Koenig W., Lodder R. A., March K., Demirovic J., Navab M., Priori S. G., Rekhter M. D., Bahr R., Grundy S. M., Mehran R., Colombo A., Boerwinkle E., Ballantyne C., Insull W. Jr., Schwartz R. S., Vogel R., Serruys P. W., Hansson G. K., Faxon D. P., Kaul S., Drexler H., Greenland P., Muller J. E., Virmani R., Ridker P. M., Zipes D. P., Shah P. K., Willerson J. T., From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part II. Circulation 2003 108 15 1772 1778 2-s2.0-0142053972 10.1161/01.CIR.0000087481.55887.C9 (Pubitemid 37296082)
6. Gravallese E. M., Osteopontin: a bridge between bone and the immune system. Journal of Clinical Investigation 2003 112 2 147 149 2-s2.0-0043245084 10.1172/JCI200319190 (Pubitemid 38056349)
7. Schoppet M., Preissner K. T., Hofbauer L. C., RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. Arteriosclerosis, Thrombosis, and Vascular Biology 2002 22 4 549 553 2-s2.0-0036120427 10.1161/01.ATV.0000012303.37971.DA (Pubitemid 34408732)
8. Steitz S. A., Speer M. Y., McKee M. D., Liaw L., Almeida M., Yang H., Giachelli C. M., Osteopontin inhibits mineral deposition and promotes regression of ectopic calcification. The American Journal of Pathology 2002 161 6 2035 2046 2-s2.0-0036900001 (Pubitemid 35434850)
9. Quercioli A., Mach F., Bertolotto M., Lenglet S., Vuilleumier N., Galan K., Pagano S., Braunersreuther V., Pelli G., Pistoia V., Bianchi G., Cittadini G., Viviani G. L., Pende A., Roux-Lombard P., Thomas A., Staub C., Ratib O., Dallegri F., Schindler T. H., Montecucco F., Receptor activator of NF- B ligand (RANKL) increases the release ofneutrophil products associated with coronary vulnerability. Thrombosis and Haemostasis 2012 107 1 124 139 2-s2.0-84855337382 10.1160/TH11-05-0324
10. Henry D. H., Costa L., Goldwasser F., Hirsh V., Hungria V., Prausova J., Scagliotti G. V., Sleeboom H., Spencer A., Vadhan-Raj S., Von Moos R., Willenbacher W., Woll P. J., Wang J., Jiang Q., Jun S., Dansey R., Yeh H., Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. Journal of Clinical Oncology 2011 29 9 1125 1132 2-s2.0-79952761418 10.1200/JCO.2010.31.3304
11. Lipton A., Fizazi K., Stopeck A. T., Henry D. H., Brown J. E., Yardley D. A., Richardson G. E., Siena S., Maroto P., Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. European Journal of Cancer 2012 48 16 3082 3092 10.1016/j.ejca.2012.08.002
12. Reiner Z., Catapano A. L., De Backer G., Graham I., Taskinen M. R., Wiklund O., Agewall S., Alegria E., Chapman M. J., Durrington P., Erdine S., Halcox J., Hobbs R., Kjekshus J., Filardi P. P., Riccardi G., Storey R. F., Wood D., ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). European Heart Journal 2011 32 14 1769 1818 10.1093/eurheartj/ehr158
13. Akdim F., van Leuven S. I., Kastelein J. J. P., Stroes E. S. G., Pleiotropic effects of statins: stabilization of the vulnerable atherosclerotic plaque? Current Pharmaceutical Design 2007 13 10 1003 1012 2-s2.0-34247884512 10.2174/138161207780487548 (Pubitemid 46696556)
14. Brown B. G., Zhao X.-Q., Sacco D. E., Albers J. J., Lipid lowering and plaque regression: new insights into prevention of plaque disruption and clinical events in coronary disease. Circulation 1993 87 6 1781 1791 2-s2.0-0027322448 (Pubitemid 23165620)
15. Ridker P. M., Danielson E., Fonseca F. A. H., Genest J., Gotto A. M. Jr., Kastelein J. J. P., Koenig W., Libby P., Lorenzatti A. J., MacFadyen J. G., Nordestgaard B. G., Shepherd J., Willerson J. T., Glynn R. J., Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. The New England Journal of Medicine 2008 359 21 2195 2207 2-s2.0-56749106312 10.1056/NEJMoa0807646
16. Crisby M., Nordin-Fredriksson G., Shah P. K., Yano J., Zhu J., Nilsson J., Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 2001 103 7 926 933 2-s2.0-0035916233 (Pubitemid 32183796)
17. Montecucco F., Di Marzo V., Da Silva R. F., Vuilleumier N., Capettini L., Lenglet S., Pagano S., Piscitelli F., Quintao S., Bertolotto M., Pelli G., Galan K., Pilet L., Kuzmanovic K., Burger F., Pane B., Spinella G., Braunersreuther V., Gayet-Ageron A., Pende A., Viviani G. L., Palombo D., Dallegri F., Roux-Lombard P., Santos R. A. S., Stergiopulos N., Steffens S., Mach F., The activation of the cannabinoid receptor type 2 reduces neutrophilic protease-mediated vulnerability in atherosclerotic plaques. European Heart Journal 2012 33 7 846 856 2-s2.0-84859496535 10.1093/eurheartj/ehr449
18. Montecucco F., Vuilleumier N., Pagano S., Lenglet S., Bertolotto M., Braunersreuther V., Pelli G., Kovari E., Pane B., Spinella G., Pende A., Palombo D., Dallegri F., MacH F., Roux-Lombard P., Anti-apolipoprotein A-1 auto-antibodies are active mediators of atherosclerotic plaque vulnerability. European Heart Journal 2011 32 4 412 421 2-s2.0-79951839869 10.1093/eurheartj/ ehq521
19. Naci H., Brugts J. J., Fleurence R., Ades A. E., Dose-comparative effects of different statins on serum lipid levels: a network meta-analysis of 256,827 individuals in 181 randomized controlled trials. European Journal of Preventive Cardiology 2013 20 4 658 670 10.1177/2047487313483600
20. Montecucco F., Lenglet S., Gayet-Ageron A., Bertolotto M., Pelli G., Palombo D., Pane B., Spinella G., Steffens S., Raffaghello L., Pistoia V., Ottonello L., Pende A., Dallegri F., Mach F., Systemic and intraplaque mediators of inflammation are increased in patients symptomatic for ischemic stroke. Stroke 2010 41 7 1394 1404 2-s2.0-77954176108 10.1161/STROKEAHA.110.578369
21. Dhore C. R., Cleutjens J. P. M., Lutgens E., Cleutjens K. B. J. M., Geusens P. P. M., Kitslaar P. J. E. H. M., Tordoir J. H. M., Spronk H. M. H., Vermeer C., Daemen M. J. A. P., Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. Arteriosclerosis, Thrombosis, and Vascular Biology 2001 21 12 1998 2003 2-s2.0-0035571591 (Pubitemid 34219753)
22. Dimitrow P. P., Jawień M., Gackowski A., The influence of statins on levels of calcification biomarkers in patients with aortic sclerosis or mild aortic stenosis. The Journal of Heart Valve Disease 2011 20 1 18 22 2-s2.0-79953829025
23. Browner W. S., Lui L.-Y., Cummings S. R., Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. Journal of Clinical Endocrinology and Metabolism 2001 86 2 631 637 2-s2.0-0035094860 10.1210/jc.86.2.631 (Pubitemid 32207471)
24. Jono S., Ikari Y., Shioi A., Mori K., Miki T., Hara K., Nishizawa Y., Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 2002 106 10 1192 1194 2-s2.0-0037015255 10.1161/01.CIR.0000031524.49139.29 (Pubitemid 34988634)
25. Schoppet M., Sattler A. M., Schaefer J. R., Herzum M., Maisch B., Hofbauer L., Increased osteoprotegerin serum levels in men with coronary artery disease. Journal of Clinical Endocrinology and Metabolism 2003 88 3 1024 1028 2-s2.0-0037338946 10.1210/jc.2002-020775 (Pubitemid 36337751)
26. Bucay N., Sarosi I., Dunstan C. R., Morony S., Tarpley J., Capparelli C., Scully S., Tan H. L., Xu W., Lacey D. L., Boyle W. J., Simonet W. S., Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes and Development 1998 12 9 1260 1268 2-s2.0-0032079445 (Pubitemid 28213402)
27. Verhoeven B. A. N., Moll F. L., Koekkoek J. A. F., van Der Wal A. C., De Kleijn D. P. V., De Vries J. P. P. M., Verheijen J. H., Velema E., Busser E., Schoneveld A., Virmani R., Pasterkamp G., Statin treatment is not associated with consistent alterations in inflammatory status of carotid atherosclerotic plaques: a retrospective study in 378 patients undergoing carotid endarterectomy. Stroke 2006 37 8 2054 2060 2-s2.0-33747161047 10.1161/01.STR.0000231685.82795.e5 (Pubitemid 44309903)
28. Tian J., Gu X., Sun Y., Ban X., Xiao Y., Hu S., Yu B., Effect of statin therapy on the progression of coronary atherosclerosis. BMC Cardiovascular Disorders 2012 12, article 70 10.1186/1471-2261-12-70
29. Cannon C. P., Steinberg B. A., Murphy S. A., Mega J. L., Braunwald E., Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. Journal of the American College of Cardiology 2006 48 3 438 445 2-s2.0-33746355566 10.1016/j.jacc.2006.04.070 (Pubitemid 44109954)
30. Tikkanen M. J., Szarek M., Fayyad R., Holme I., Cater N. B., Faergeman O., Kastelein J. J. P., Olsson A. G., Larsen M. L., Lindahl C., Pedersen T. R., Total cardiovascular disease burden: comparing intensive with moderate statin therapy: insights from the IDEAL (Incremental Decrease in End Points through Aggressive Lipid Lowering) trial. Journal of the American College of Cardiology 2009 54 25 2353 2357 2-s2.0-71649105479 10.1016/j.jacc.2009.08.035